Sibel Ozdemir | Pharmacology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Sibel Ozdemir — Yunus Emre State Hospital, Turkey

Sibel Ozdemir
Affiliation Yunus Emre State Hospital
Country Turkey
Scopus ID 60749146700
Subject Area Pharmacology
Event Health Scientists Awards
ORCID 0009-0003-4671-0964

Sibel Ozdemir is a researcher associated with Yunus Emre State Hospital whose recent scholarly work connects neurology with pharmacological investigation. Published studies have examined antiseizure medicines, experimental seizure models, medication combinations, and potential interactions involving clopidogrel, valproic acid, and levetiracetam. [1] [2]

Abstract

Sibel Ozdemir is a researcher affiliated with Yunus Emre State Hospital in Turkey whose documented work addresses pharmacology, neurology, and experimental seizure research. Her recent publications examine interactions between antiplatelet and antiseizure medicines and pharmacological effects in experimental models. This profile summarizes her research themes, publications, and recognition context in research.

Keywords

Epilepsy, valproic acid, levetiracetam, clopidogrel, pentylenetetrazol, freezing behavior, antiseizure medicines, anticonvulsant efficacy, experimental seizure models, behavioral effects, drug interactions, neurology, pharmacology, and clinical pharmacology. These terms reflect the themes identified in her recent research publications. [1] [2]

Introduction

Sibel Ozdemir is affiliated with the Department of Neurology at Yunus Emre State Hospital, Eskişehir, Türkiye. Her recent scholarly record includes investigations involving antiseizure medicines, drug interactions, and neurological models. These studies connect clinical neurology with pharmacological questions concerning treatment combinations and biological responses in experimental research settings. [1] [2]

Research Profile

Sibel Ozdemir’s documented research profile centers on neurology and pharmacology, with publications involving antiseizure therapy, experimental seizure models, and medication interactions. PubMed records identify her ORCID as 0009-0003-4671-0964 and associate recent work with Yunus Emre State Hospital. The available evidence supports a clinically oriented pharmacological research profile in clinical practice. [1]

Research Contributions

Sibel Ozdemir contributes to research examining pharmacological effects in neurological conditions. A 2026 study evaluated clopidogrel alongside valproic acid and levetiracetam in a pentylenetetrazol-induced seizure model, while another study examined differential effects of valproic acid and levetiracetam on freezing behavior. These studies address medication efficacy and drug interactions in pharmacology. [1] [2]

Publications

Sibel Ozdemir is listed as an author on publications concerning antiseizure pharmacology and neurological experimental models. Her 2026 International Journal of Molecular Sciences article investigated clopidogrel with valproic acid and levetiracetam, while a 2026 Journal of Biotechnology and Strategic Health Research article examined valproic acid and levetiracetam effects in rats. [1] [2]

Research Impact

Sibel Ozdemir’s research has potential relevance to pharmacological decision-making by investigating how neurological medicines behave in experimental combinations. The documented studies provide evidence about antiseizure efficacy and medication interactions, while their experimental designs also illustrate translational questions that may require further clinical investigation before broader conclusions are drawn. [1] [2]

Award Suitability

Sibel Ozdemir’s publication activity aligns with an Innovative Research Award profile through its focus on pharmacological questions in neurological research and experimental models. The publications demonstrate investigation of drug combinations and antiseizure effects. Award recognition should consider originality, methodological contribution, publication record, and relevance of the submitted research evidence overall. [1] [2]

Conclusion

Sibel Ozdemir’s available scholarly record presents a research trajectory connecting clinical neurology with pharmacology and experimental seizure research. Her recent publications provide documented evidence of work on antiseizure medicines and drug interactions. Continued publication, independent validation, and clinical translation would further clarify the broader significance of these research contributions today. [1] [2]

References

    1. Özdemir, S., Bolayır, E., & Şahin İnan, Z. D. (2026). Effects of Clopidogrel on the Anticonvulsant Efficacy of Valproic Acid and Levetiracetam in a PTZ-Induced Seizure Model. International Journal of Molecular Sciences, 27(14), 6415.
      https://doi.org/10.3390/ijms27146415
    2. Gürkan, İ. M., Demir Cevizlidere, B., Çalişkan, S., Özdemir, S., & Özdemir, H. (2026). Effects of nano-hydroxyapatite-coated PRF on gingiva-derived mesenchymal stem cells: In vitro study. International Journal of Molecular Sciences, 27(13), 5736.
      https://doi.org/10.3390/ijms27135736
    3. ORCID. (n.d.). ORCID record: Sibel Ozdemir, ORCID 0009-0003-4671-0964.
      https://orcid.org/0009-0003-4671-0964
    4. Elsevier. (n.d.). Scopus author details: Sibel Ozdemir, Author ID 60749146700. Scopus.
      https://www.scopus.com/authid/detail.uri?authorId=60749146700

Raphael Duval | Pharmacology | Research Excellence Award

Published on by Health Scientists

Prof. Dr. Raphael Duval | Pharmacology | Research Excellence Award

Dean | Université de Lorraine | France

Raphaël E. Duval is a senior academic leader and clinical microbiologist serving as Professor and Dean of the Faculty of Pharmacy at Université de Lorraine, France. His expertise spans infectiology, virology, cellular biology, and pharmaceutical sciences, with a strong focus on the discovery and development of innovative anti-infective and anticancer therapeutic agents. His research is widely disseminated through international peer-reviewed journals, scholarly book chapters, patents, and invited scientific communications, reflecting significant academic influence and citation impact. He actively collaborates with multidisciplinary teams across academia and industry at national and international levels. Recognized through prestigious scientific awards and fellowships, his work contributes to advancing therapeutic innovation, strengthening infectious disease management, and addressing major public health challenges with meaningful societal and clinical impact. He has 4909 citations from 98 documents with an h-index of 34.

Citation Metrics (Scopus)

4909
3500
2000
1000
0

Citations

4,909

Documents

98

h-index

34

Citations

Documents

h-index

View Google Scholar Profile
 View Scopus Profile
 View Orcid Profile

Featured Publications

Sina Andalib | Pharmacology | Best Researcher Award

Published on by Health Scientists

Assoc. Prof. Dr. Sina Andalib | Pharmacology | Best Researcher Award

correspond author | Zanjan university of medical sciences | Iran

Dr. Sina Andalib is an Associate Professor at the Department of Pharmacology, Pharmacy Faculty, Zanjan University of Medical Sciences, Iran. He earned his Doctor of Veterinary Medicine (DVM) from Tabriz Azad University in 2005, focusing on anti-inflammatory effects of statins, and completed his PhD at Tabriz University of Medical Sciences in 2013, investigating the cardioprotective effects of Atorvastatin in isoproterenol-induced heart failure in rats. Dr. Andalib’s research spans pharmacology, neurodegenerative diseases, drug delivery systems, and natural product therapeutics, with a particular focus on Alzheimer’s disease, Parkinson’s disease, diabetes, and cancer. He has supervised numerous PhD and PharmD theses exploring innovative nanoparticle-based drug delivery, herbal and synthetic compound interventions, and molecular mechanisms underlying neuroprotection and cardioprotection. His work has been published extensively in high-impact international journals including ACS Chemical Neuroscience, Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, and European Journal of Pharmacology, covering topics such as nanocomposite hydrogels for wound healing, fullerene-based interventions in Alzheimer’s models, and polypharmacological effects of anticancer compounds. Dr. Andalib has contributed to several internationally collaborative projects, including the development of nanocomposites for neuroprotection and polypharmacological studies of anticancer compounds in organoid models. He has received recognition for his scientific contributions in pharmacology and neurotherapeutics and serves on editorial boards of peer-reviewed journals in pharmacology and drug delivery research. In addition to his research, he holds leadership roles at Zanjan University, including Head of the Department of Pharmacology and Toxicology and Head of the Education Development Office, fostering academic development and innovative research in pharmaceutical sciences. He has 751 citations from 39 documents with an h-index of 15.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Danafar, H., Sharafi, A., Kheiri Manjili, H., & Andalib, S. (2017). Sulforaphane delivery using mPEG–PCL co-polymer nanoparticles to breast cancer cells.

2. Garjani, A., Fathiazad, F., Zakheri, A., Akbari, N. A., Azarmie, Y., Fakhrjoo, A., et al. (2009). The effect of total extract of Securigera securidaca L. seeds on serum lipid profiles, antioxidant status, and vascular function in hypercholesterolemic rats.

3. Barzegar-Jalali, M., Alaei-Beirami, M., Javadzadeh, Y., Mohammadi, G., et al. (2012). Comparison of physicochemical characteristics and drug release of diclofenac sodium–eudragit® RS100 nanoparticles and solid dispersions.

4. Garjani, A., Andalib, S., Biabani, S., Soraya, H., Doustar, Y., & Garjani, A., et al. (2011). Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat.

5. Abedimanesh, N., Asghari, S., Mohammadnejad, K., Daneshvar, Z., et al. (2021). The anti-diabetic effects of betanin in streptozotocin-induced diabetic rats through modulating AMPK/SIRT1/NF-κB signaling pathway.

Paramanna Poojari | Pharmacology | Best Researcher Award

Published on by Health Scientists

Mr. Paramanna Poojari | Pharmacology | Best Researcher Award

Research Scholar | Karnatak University Dharwad | India

Dr. Paramanna Poojari, currently serving as a Research Scholar in the Department of Biochemistry at Karnatak University Dharwad, has built a strong academic and professional foundation in the fields of biochemistry, microbiology, nanotechnology, and cell culture. He holds a postgraduate degree in biochemistry and has specialized in experimental and applied research with a focus on nanoscience, cancer biology, drug delivery systems, and phytoremediation. Dr. Poojari’s research explores the potential of nanoparticles, plant tissue culture, antibiotic sensitivity testing, and nanomaterial characterization, with the objective of advancing innovative solutions for healthcare, pharmaceuticals, and environmental sustainability. His scholarly contributions include publications in highly regarded international journals indexed in Scopus, Google Scholar, and UGC CARE list, such as Drug Delivery Science and Technology, Water Air and Soil Pollution, and Dispersion Science and Technology, with a citation index of 24 and an h-index of 3. He has also contributed a book chapter published with ISBN: 9781032699882, further strengthening his academic profile. In recognition of his growing expertise, Dr. Poojari has been entrusted with editorial and peer-review responsibilities for reputed publishers including Elsevier and Springer Nature, underscoring his role in maintaining research quality and scientific integrity. His collaborations with nanotechnology laboratories have enabled interdisciplinary exploration bridging life sciences and material sciences. With patents under preparation and continued innovation in biotechnology applications, Dr. Poojari exemplifies a dedicated young scientist committed to impactful research. His academic achievements and professional contributions highlight his potential as a future leader in health sciences and allied fields. He has 18 citations from 8 documents with an h-index of 3.

Profile: Google Scholar | Scopus | ORCID

Publications

1. Ganeshkar, M. P., Gaddigal, A. T., Shivappa, P., Poojari, P. B., Goder, P. H., … (2023). Biocompatibility assessment of Rutin and PEG loaded novel nanoceria on human erythrocytes and human myeloid leukemia (U937) cells. Journal of Drug Delivery Science and Technology, 86, 104761.

2. Gaddigal, A. T., Shivappa, P., Ganeshkar, M. P., Mirjankar, M. R., Poojari, P. B., … (2024). Green synthesis of copper oxide nanoparticles using Simarouba glauca leaf extract, characterization and screening for their biological applications. Journal of Dispersion Science and Technology, 1–15.

3. Mirjankar, M. R., Pattar, S. V., Gaddigal, A. T., Shivappa, P., Poojari, P. B., … (2023). Phytoremediation of copper contaminated water using Pistia stratiotes and emphasis of thermal stability in response to metal stress. Water Conservation Science and Engineering, 8(1), 24.

4. Mirjankar, M. R., Pattar, S. V., Gaddigal, A. T., Shivappa, P., Poojari, P. B., … (2023). Isolation of culturable endophytic bacteria from the roots of Aloe vera L. (Aloe barbadensis Miller) and their application in phytodegradation of xenobiotics. Water, Air, & Soil Pollution, 234(7), 451.

5. Shivappa, P., Mirjankar, M. R., Gaddigal, A. T., Ganeshkar, M. P., Poojari, P. B., … (2023). Bismuth nanoparticle synthesis utilizing hydroalcoholic Endocomia macrocoma leaf extract to evaluate their antimicrobial, antioxidant, and anticancer properties. Journal of Dispersion Science and Technology, 1–15.